Domestic companies’ trouble in Brilinta’s substance patent

It was known although domestic pharmaceutical companies are competing over nullifying the patent of the AstraZeneca’s anticoagulant, ‘Brilinta,’ they are observed to have difficulties on the most important one, the substance patent. Thus, a part of the field has criticized thoughtless suits can hinder development of the industry.

On the 25^th, the Intellectual Property Tribunal accepted the app...